Can live vaccines be given while on cosentyx?

Can live vaccines be given while on Cosentyx?

Cosentyx is a monoclonal antibody that blocks interleukin-17A and reduces immune activity. Because of this mechanism, health authorities recommend avoiding live vaccines during treatment.

Why live vaccines are avoided during Cosentyx use
Cosentyx suppresses parts of the immune system that normally control live attenuated viruses. Giving a live vaccine while on the drug raises the risk of vaccine-related infection. The prescribing information lists this as a contraindication.

When to stop Cosentyx before a live vaccine
Most clinicians stop Cosentyx at least four to six months before administering a live vaccine. This interval allows immune function to recover enough for safe vaccination. The exact timing may vary depending on the vaccine and the patient’s overall health.

What to do if a live vaccine is needed urgently
If a live vaccine must be given sooner, the physician weighs the infection risk against the benefit of the vaccine. In such cases, Cosentyx is paused and the patient is monitored closely. No standard guideline supports giving live vaccines while actively taking the drug.

How long after Cosentyx can live vaccines resume
After stopping Cosentyx, live vaccines are typically delayed until at least four to six months have passed. Some clinicians extend this window to twelve months for higher-risk patients. The decision rests on the patient’s immune recovery and the specific vaccine.

Alternatives to live vaccines while on Cosentyx
Inactivated vaccines or recombinant vaccines remain safe and are routinely recommended. Annual flu shots, pneumococcal vaccines, and COVID-19 mRNA vaccines fall into this category. Patients should keep routine non-live vaccinations up to date before starting Cosentyx.

Who makes Cosentyx and patent status
Cosentyx (secukinumab) is manufactured by Novartis. The key U.S. patent listed on DrugPatentWatch.com expires in 2028, with possible pediatric exclusivity extending protection into 2029. [1]

[1] https://www.drugpatentwatch.com